| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 842.0 | 706.3 |
| Gross profit | 632.1 | 510.1 |
| Profit before tax | 177.2 | 122.8 |
| Net income | 141.1 | 87.6 |
| EPS (diluted, $ a share) | $2.03 | $1.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +61.1% |
|---|---|
| Revenue, year on year | +19.2% |
| Gross margin | 75.1% |
| Operating margin | 22.5% |
10-Q filed with the SEC, NASDAQ: PODD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Insulet Corp: key numbers
- Share price
- $145.29Close, Nov 16
- Market cap
- $10.1B
- Shares outstanding
- 69.37MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Insulet Corp
All →Insulet Financial Results
Insulet reported Q3 2026 revenue of $842 million, a 19.2% increase year-over-year, driven by strong Omnipod sales in both U.S. and international markets. Alongside the earnings, the company announced a new $1 billion stock repurchase program authorized through 2028, with $400 million planned for the fourth quarter of 2026.
Insulet $725M Debt Financing with Morgan Stanley Senior Funding, Inc.
Insulet Corporation entered into a ninth amendment to its credit agreement to refinance $475 million in existing term loans with new term loans at a 0.25% lower interest rate margin. Additionally, the company increased its revolving credit facility commitments by $250 million to a total of $750 million and reduced the applicable interest rate margins for revolving loans.
- Value
- $725M
- Counterparty
- Morgan Stanley Senior Funding, Inc.
Insulet Executive Compensation
Insulet Corporation adopted a new Nonqualified Deferred Compensation Plan effective January 1, 2027, for a select group of management and highly compensated employees, including named executive officers. The plan allows participants to voluntarily defer up to 60% of their cash compensation and permits the company to make discretionary matching or nonelective contributions subject to a two-year vesting schedule.